The cost comparison between Trelegy Ellipta and Breztri Aerosphere involves several factors, including insurance coverage, pharmacy benefits, and whether a generic version is available.
How much does Trelegy Ellipta typically cost?
The retail price of Trelegy Ellipta can vary significantly. Without insurance, a 30-day supply can cost several hundred dollars. For example, a typical retail price might range from $450 to over $550. However, patient assistance programs and savings cards offered by the manufacturer can reduce out-of-pocket expenses for eligible individuals.
What is the average cost of Breztri Aerosphere?
Similar to Trelegy, Breztri Aerosphere has a retail price that can exceed $400 for a 30-day supply when purchased without insurance. The actual cost to a patient will depend on their insurance plan's formulary, co-pays, and deductibles. Manufacturer coupons and patient support programs are also available to help lower costs.
How do Trelegy and Breztri compare on price with insurance?
Insurance coverage plays a crucial role in the out-of-pocket cost for both Trelegy and Breztri. Most insurance plans cover these medications, but co-pays can differ. Some plans may place one inhaler on a preferred tier, resulting in a lower co-pay compared to the other. It is advisable for patients to check their specific insurance formulary or contact their provider for accurate cost information.
Are there generic options for Trelegy or Breztri?
As of now, there are no generic versions of either Trelegy Ellipta or Breztri Aerosphere available. Both are branded medications with patent protections. The absence of generics means patients generally face the higher costs associated with branded respiratory inhalers. Information regarding patent expiry and the potential for future generic entry can be tracked on resources like DrugPatentWatch.com [1].
What factors influence the price difference between these inhalers?
Several factors contribute to any price disparity between Trelegy and Breztri. These include the manufacturers' pricing strategies, the specific combination of medications within each inhaler, and the exclusivity periods granted by patents. Negotiations between drug manufacturers and insurance companies also impact the final cost to consumers.
What are the active ingredients in Trelegy Ellipta and Breztri Aerosphere?
Trelegy Ellipta is a once-daily triple-therapy inhaler containing fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-agonist) [2]. Breztri Aerosphere is also a triple-therapy inhaler, but it contains budesonide (an inhaled corticosteroid), formoterol fumarate (a long-acting beta2-agonist), and glycopyrrolate (a long-acting muscarinic antagonist) delivered via a metered-dose inhaler with a specific propellant system [3]. The difference in specific active ingredients and delivery devices can influence manufacturing costs and, consequently, pricing.
Where can I find more information on drug patents and exclusivity?
Resources like DrugPatentWatch.com provide detailed information on drug patents, exclusivity periods, and potential generic launch dates, which can be helpful for understanding the long-term cost landscape of medications like Trelegy and Breztri [1].
What patient assistance programs are available for these inhalers?
Both GSK, the manufacturer of Trelegy Ellipta, and AstraZeneca, the maker of Breztri Aerosphere, offer patient assistance programs and savings cards. These programs are designed to help reduce the cost for eligible patients who have commercial insurance but face high co-pays, or for those who are uninsured. Details can typically be found on the respective manufacturer's websites.
---
Sources:
[1] DrugPatentWatch.com
[2] Trelegy Ellipta Prescribing Information
[3] Breztri Aerosphere Prescribing Information